Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Pharmicell Co., Ltd.
Cellgram-DC-PC is an autologous dendritic cell-based cancer immunotherapy developed for patients with metastatic castration-resistant prostate cancer (mCRPC). This was a Phase 1, single-center, open-label clinical trial designed to characterize the safety profile of Cellgram-DC-PC following administration in patients with mCRPC.
Age
19–79
Sex
MALE
Healthy volunteers
Not accepted